Compare Hershey Co (HSY) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hershey Co vs GeneDx Holdings Corp — how do they compare? Hershey Co trades at $162.74 (market cap $32.66B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Hershey Co is far larger — about 16.2× GeneDx Holdings Corp's market cap, and Hershey Co pays a 3.57% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hershey Co for 135 Days and GeneDx Holdings Corp for 19 Days on average.
| HSY | WGS | |
|---|---|---|
Market Cap | $32.66B | $2.02B |
Volume | 1,578,237 | 734,640 |
Sector | Consumer Staples | Health |
52-Week High | $236.28 | $167.51 |
52-Week Low | $157.61 | $34.51 |
Typical Hold Time | 135 Days | 19 Days |
Enterprise Value | $37.79B | $2.05B |
Dividend Yield | 3.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hershey (HSY) trades at $162.74, up 1.5% with bearish technical signals but strong fundamentals. The stock shows consistent earnings beats (3 of last 4 quarters) with Q3 2026 results pending. Revenue grew to $11.69B in 2025, though net margin compressed to 7.55% from 19.82% in 2024. Analyst consensus targets $204.62 (25.7% upside) with 65.7% hold ratings. Recent news highlights dividend resumption and international leadership changes.
HSY presents a mixed outlook: valuation appears reasonable (P/E 22.2) with strong brand positioning, but faces margin pressure from commodity costs. The technical bearish trend near key support at $161 suggests near-term caution. Long-term investors may find value given dividend growth resumption and consistent market share, though cocoa price volatility remains a key risk.
GeneDx (WGS) trades at $67.33, down 1.75% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows negative net margins. Recent news highlights product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus is strongly bullish with an $81 price target, fundamental risks remain due to negative profitability and high valuation multiples. The stock offers potential upside if operational improvements continue, but investors face execution risk amid ongoing losses and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
